STTK
Shattuck Labs, Inc. NASDAQ Listed Oct 9, 2020$4.95
+4.43%
vs $4.74
Mkt Cap $344.4M
52w Low $0.73
59.0% of range
52w High $7.88
50d MA $6.21
200d MA $4.13
P/E (TTM)
—
EV/EBITDA
—
P/B
4.2x
Debt/Equity
0.0x
ROE
-59.2%
P/FCF
-8.6x
RSI (14)
39.40
ATR (14)
$0.58
Beta
1.29
50d MA
$6.21
200d MA
$4.13
Avg Volume
943.0K
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
500 West 5th Street · Austin, TX 78703 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 6.68 | -0.4% | -6.3% | +9.4% | +2.5% | -5.7% | +2.0% | — |
| Mar 5, 2026 | BMO | -0.12 | -0.12 | +0.0% | 4.73 | -3.6% | +7.8% | +17.5% | +0.5% | -1.0% | -1.3% | — |
| Nov 6, 2025 | BMO | -0.15 | -0.14 | +6.7% | 2.04 | -2.0% | -3.9% | +1.0% | -4.5% | +4.8% | -3.0% | — |
| Aug 14, 2025 | BMO | -0.25 | -0.24 | +4.0% | 0.81 | -1.3% | +6.1% | +16.2% | +2.0% | +1.0% | -1.9% | — |
| May 1, 2025 | BMO | -0.29 | -0.27 | +6.9% | 0.99 | +0.0% | +9.2% | -7.8% | +0.3% | -12.9% | +0.3% | — |
| Mar 27, 2025 | BMO | -0.38 | -0.37 | +2.6% | 1.18 | -2.5% | -3.4% | -7.0% | -10.4% | -11.0% | +16.3% | — |
| Nov 14, 2024 | BMO | -0.41 | -0.33 | +19.5% | 1.22 | +2.5% | +12.3% | -9.5% | -10.5% | +2.7% | -2.6% | — |
| Aug 1, 2024 | BMO | -0.41 | -0.42 | -2.4% | 3.98 | -0.5% | -5.3% | -3.2% | -16.2% | +1.0% | -2.3% | — |
| May 2, 2024 | BMO | -0.47 | -0.37 | +21.3% | 10.86 | +1.8% | +2.2% | -2.9% | +3.7% | -3.8% | -2.4% | — |
| Feb 29, 2024 | BMO | -0.51 | -0.41 | +19.6% | 8.99 | -1.0% | -2.9% | +10.5% | -1.9% | +1.0% | -0.9% | — |
| Nov 9, 2023 | BMO | -0.52 | -0.65 | -25.0% | 2.37 | -5.5% | -23.2% | +1.1% | +2.7% | +10.1% | +3.8% | — |
| Aug 10, 2023 | BMO | -0.52 | -0.50 | +3.8% | 2.43 | -0.8% | -8.6% | -2.3% | -3.2% | +2.9% | -4.6% | — |
| May 9, 2023 | BMO | -0.61 | -0.49 | +19.7% | 2.70 | +0.7% | +5.6% | -2.1% | +0.4% | -7.1% | +0.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27 | Cantor Fitzgerald | Initiates | Overweight | — | $7.74 | $7.90 | +2.1% | -0.3% | -2.5% | -5.8% | +0.8% | -2.2% |
| Apr 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.53 | $7.62 | +1.2% | +4.6% | -1.5% | -0.1% | -1.3% | +1.2% |
| Mar 13 | Citigroup | Maintains | Neutral → Neutral | — | $6.13 | $6.21 | +1.3% | -2.3% | +0.5% | -1.2% | +1.5% | +1.0% |
| Mar 6 | Wedbush | Maintains | Outperform → Outperform | — | $5.10 | $5.27 | +3.3% | +17.5% | +0.5% | -1.0% | -1.3% | +4.3% |
| Jan 6 | Citigroup | Maintains | Neutral → Neutral | — | $3.89 | $3.96 | +1.8% | +2.3% | +20.6% | -3.3% | +2.4% | -3.4% |
| Dec 1 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $2.10 | $2.25 | +7.1% | +14.8% | +2.9% | +4.8% | +14.2% | +4.4% |
| Aug 14 | Leerink Partners | Maintains | Outperform → Outperform | — | $0.81 | $0.80 | -1.3% | +6.1% | +16.2% | +2.0% | +1.0% | -1.9% |
| Aug 14 | Needham | Maintains | Hold → Hold | — | $0.81 | $0.80 | -1.3% | +6.1% | +16.2% | +2.0% | +1.0% | -1.9% |
| Mar 27 | Needham | Maintains | Hold → Hold | — | $1.18 | $1.15 | -2.5% | -3.4% | -7.0% | -10.4% | -11.0% | +16.3% |
| Mar 27 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.18 | $1.15 | -2.5% | -3.4% | -7.0% | -10.4% | -11.0% | +16.3% |
| Oct 2 | Needham | Downgrade | Buy → Hold | — | $1.92 | $1.80 | -6.2% | -34.9% | +2.4% | -4.7% | -7.4% | +11.5% |
| Oct 2 | Citigroup | Downgrade | Buy → Neutral | — | $1.92 | $1.80 | -6.2% | -34.9% | +2.4% | -4.7% | -7.4% | +11.5% |
| Oct 1 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $3.49 | $1.40 | -59.9% | -45.0% | -34.9% | +2.4% | -4.7% | -7.4% |
| Aug 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.61 | $3.60 | -0.3% | -2.5% | -3.1% | +2.3% | +2.9% | -4.5% |
| Aug 15 | Citigroup | Maintains | Buy → Buy | — | $3.12 | $3.14 | +0.6% | +5.4% | +2.1% | +3.9% | -5.4% | +3.9% |
| Aug 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.77 | $3.56 | -5.6% | -3.2% | -16.2% | +1.0% | -2.3% | +1.0% |
| Aug 2 | Needham | Maintains | Buy → Buy | — | $3.77 | $3.56 | -5.6% | -3.2% | -16.2% | +1.0% | -2.3% | +1.0% |
| Jun 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.59 | $4.52 | -1.5% | -9.2% | +4.8% | -9.4% | -10.1% | +6.5% |
| Jun 17 | Citigroup | Maintains | Buy → Buy | — | $6.19 | $5.92 | -4.4% | -19.5% | -7.8% | -9.2% | +4.8% | -9.4% |
| Jun 14 | Needham | Maintains | Buy → Buy | — | $6.84 | $6.81 | -0.4% | -9.5% | -19.5% | -7.8% | -9.2% | +4.8% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.48 | $8.47 | -0.1% | -3.8% | -3.9% | +1.0% | -5.9% | +3.6% |
| May 14 | Needham | Maintains | Buy → Buy | — | $10.35 | $10.44 | +0.9% | -18.1% | -3.8% | -3.9% | +1.0% | -5.9% |
| May 3 | Needham | Maintains | Buy → Buy | — | $11.10 | $11.34 | +2.2% | -2.9% | +3.7% | -3.8% | -2.4% | +1.6% |
| May 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.86 | $11.06 | +1.8% | +2.2% | -2.9% | +3.7% | -3.8% | -2.4% |
| Apr 9 | Needham | Maintains | Buy → Buy | — | $8.79 | $8.86 | +0.8% | +2.4% | +8.4% | -1.5% | -2.8% | -2.7% |
| Mar 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.73 | $9.17 | +5.0% | +10.5% | -1.9% | +1.0% | -0.9% | -1.1% |
| Mar 1 | Needham | Maintains | Buy → Buy | — | $8.73 | $9.17 | +5.0% | +10.5% | -1.9% | +1.0% | -0.9% | -1.1% |
| Feb 13 | Needham | Maintains | Buy → Buy | — | $8.94 | $9.10 | +1.8% | -5.4% | +6.0% | +0.2% | +6.7% | -4.4% |
| Feb 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.94 | $9.10 | +1.8% | -5.4% | +6.0% | +0.2% | +6.7% | -4.4% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.22 | $2.20 | -0.9% | -2.3% | -3.2% | +2.9% | -4.6% | +1.5% |
| Aug 11 | Needham | Maintains | Buy → Buy | — | $2.22 | $2.20 | -0.9% | -2.3% | -3.2% | +2.9% | -4.6% | +1.5% |
| Jun 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.88 | $2.90 | +0.7% | -2.1% | +5.0% | -1.0% | -2.4% | -0.3% |
| Jun 6 | Needham | Maintains | Buy → Buy | — | $2.88 | $2.90 | +0.7% | -2.1% | +5.0% | -1.0% | -2.4% | -0.3% |
| May 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.77 | $2.66 | -4.0% | -1.8% | +5.5% | -3.5% | +3.6% | -1.4% |
| Apr 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.83 | $2.93 | +3.5% | -1.1% | +4.6% | +0.7% | -1.7% | +0.0% |
| Apr 20 | Needham | Maintains | Buy → Buy | — | $2.83 | $2.93 | +3.5% | -1.1% | +4.6% | +0.7% | -1.7% | +0.0% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.94 | $2.94 | +0.0% | +2.0% | -4.0% | +2.4% | +1.0% | +0.7% |
| Feb 24 | Needham | Maintains | Buy → Buy | — | $4.54 | $4.67 | +2.9% | +0.4% | +1.8% | +1.7% | -3.6% | -9.7% |
| Feb 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.54 | $4.67 | +2.9% | +0.4% | +1.8% | +1.7% | -3.6% | -9.7% |
| Feb 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.41 | $4.43 | +0.6% | +2.9% | +0.2% | +0.1% | -2.2% | -2.8% |
| Aug 31 | BTIG | Maintains | Buy → Buy | — | $3.03 | $3.31 | +9.2% | +7.3% | -0.6% | +0.6% | +0.9% | +1.8% |
| Aug 12 | Needham | Maintains | Buy → Buy | — | $3.71 | $3.72 | +0.3% | +1.6% | +3.4% | +0.8% | -7.9% | -3.3% |
| Jun 1 | Citigroup | Maintains | Buy → Buy | — | $2.86 | $2.98 | +4.2% | +0.3% | +6.6% | +5.6% | -0.3% | +23.9% |
| May 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.84 | $4.14 | +7.8% | +2.6% | -1.8% | -0.8% | -7.0% | -7.3% |
| Mar 16 | Needham | Maintains | Buy → Buy | — | $4.43 | $4.50 | +1.6% | +6.8% | +6.1% | +4.6% | -7.8% | +3.1% |
| Apr 14 | Berenberg | Maintains | Buy → Buy | — | $32.11 | $33.71 | +5.0% | +3.3% | -4.5% | -5.3% | -2.9% | +1.2% |
| Jan 11 | Evercore ISI | Maintains | Outperform → Outperform | — | $40.62 | $40.39 | -0.6% | +3.7% | +8.0% | +4.1% | -1.8% | -2.8% |
| Nov 3 | Citigroup | Maintains | Buy → Buy | — | $26.87 | $26.86 | -0.0% | +4.1% | +1.6% | -1.7% | -4.1% | -12.5% |
| Nov 3 | TD Cowen | Maintains | Outperform → Outperform | — | $26.87 | $26.86 | -0.0% | +4.1% | +1.6% | -1.7% | -4.1% | -12.5% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 9, 2026 | SIEGALL CLAY B | — | Buy | 62,500 | $4.00 | $250K | 318,608 | +18.18% | +4.43% |
| May 12, 2026 | Pandite Arundathy N. | Chief Medical Officer | Sell | 30,000 | $6.61 | $198K | 166,219 | -6.15% | -1.30% |
| May 12, 2026 | Shukla Abhinav A. | Chief Technical Officer | Sell | 2,032 | $7.01 | $14K | 81,258 | -6.15% | -1.30% |
8-K
Shattuck Labs, Inc. -- 8-K Filing
Jun 11
8-K
Shattuck Labs, Inc. -- 8-K Filing
Jun 2
8-K · 2.02
!! High
Shattuck Labs, Inc. -- 8-K 2.02: Earnings Results
Shattuck Labs reported Q1 2026 financial results, providing investors with updated performance metrics on revenue, expenses, and operational progress.
May 7
8-K
Shattuck Labs, Inc. -- 8-K Filing
Shattuck Labs (STTK) expects Phase 1 SL-325 data in Q2 2026 and plans Phase 2 initiation for Crohn's disease in Q3 2026, representing pipeline advancement for the clinical-stage biotech.
Mar 5
8-K
Shattuck Labs, Inc. -- 8-K Filing
Shattuck Labs shareholders must submit shareholder proposals by February 27, 2026 for inclusion in the 2026 proxy statement.
Feb 5
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 2,277,176 | $15M | New | Mar 2026 |
| 2 | Pinnacle Associates Ltd | 1,368,223 | $9M | Added | Mar 2026 |
| 3 | Aberdeen Group Plc | 1,159,321 | $7M | Added | Mar 2026 |
| 4 | Point72 Asset Management | 1,031,049 | $7M | Reduced | Mar 2026 |
| 5 | Clark Estates Inc/ny | 1,475,648 | $5M | — | Dec 2025 |
| 6 | Millennium Management | 763,745 | $5M | Added | Mar 2026 |
| 7 | Susquehanna International Group, Llp | 715,965 | $5M | Added | Mar 2026 |
| 8 | Renaissance Technologies Llc | 604,500 | $4M | Added | Mar 2026 |
| 9 | Marshall Wace, Llp | 581,471 | $4M | Added | Mar 2026 |
| 10 | S&g Foundation | 435,749 | $3M | New | Mar 2026 |
| 11 | Fmr Llc | 392,500 | $3M | — | Mar 2026 |
| 12 | Two Sigma Investments, Lp | 316,012 | $2M | Reduced | Mar 2026 |
| 13 | Algert Global Llc | 286,072 | $2M | New | Mar 2026 |
| 14 | Acadian Asset Management Llc | 183,246 | $1M | Added | Mar 2026 |
| 15 | Citadel Advisors Llc | 148,021 | $952K | Added | Mar 2026 |
| 16 | Qube Research & Technologies Ltd | 126,798 | $815K | Added | Mar 2026 |
| 17 | Northern Trust Corp | 126,061 | $811K | Reduced | Mar 2026 |
| 18 | Barclays Plc | 119,879 | $771K | New | Mar 2026 |
| 19 | Hrt Financial Lp | 90,698 | $583K | New | Mar 2026 |
| 20 | Bank Of New York Mellon Corp | 89,774 | $577K | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$344.4M
Enterprise Value
$268.0M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.10x
P/B
4.18x
P/S
344.45x
P/FCF
-8.62x
EV/EBITDA
—
Shares Out
69.6M
Financials (TTM)
Revenue
$1.0M
Net Income
-$49.9M
EBITDA
-$46.2M
Free Cash Flow
-$40.0M
Op Cash Flow
-$39.9M
EPS Basic
$-0.70
EPS Diluted
$-0.63
EPS Forward
$-0.52
Gross Margin
-82.0%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$91.0M
Total Liab.
$8.6M
Total Equity
$82.4M
Cash
$78.1M
LT Debt
$1.6M
Book Value/Sh
$1.18
Debt/Equity
0.02x
Current Ratio
11.70
Quick Ratio
11.70
Returns & Growth
ROE
-59.2%
ROA
-53.6%
ROIC
-61.3%
Rev Growth YoY
-82.5%
EPS Growth YoY
+53.0%
Price Returns
2W
-10.8%
1M
-16.8%
3M
+51.8%
6M
+183.3%
12M
+489.1%
Technicals
52W High
$7.88
52W Low
$0.73
50d MA
$6.21
200d MA
$4.13
RSI (14)
39.40
ATR (14)
$0.58
Beta
1.29
Avg Volume
943K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$16.50
High
$18.00
Low
$15.00
Median
$16.50
Data updated apr 27, 2026 3:24am
· Source: financialmodelingprep.com